ArticleACS chemical neuroscience2020
Fluorine-18-Labeled Antibody Ligands for PET Imaging of Amyloid-β in Brain.
Article in ACS chemical neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 53 citations in OpenAlex.
- A novelEJNMMI radiopharmacy and chemistry · 2026Article
- Pretargeted brain PET imaging reveals amyloid-β pathology using a TCO-modified antibody and a fluorine-18-labeled tetrazine.Translational neurodegeneration · 2025Article
- Pretargeted Immuno-PET Enables Monoclonal Antibody Imaging Beyond the Blood-Brain Barrier.Molecular pharmaceutics · 2025Article
- Bispecific brain-penetrant antibodies for treatment of Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2025Review
- Fluorine-18 ImmunoPET Imaging of Antibody Brain Kinetics and Amyloid-Beta Pathology.ACS pharmacology & translational science · 2025Article
- PET imaging of platelet derived growth factor receptor β in lung fibrosis.EJNMMI radiopharmacy and chemistry · 2025Article
- Synthesis and preclinical evaluation of gastrin releasing peptide receptor antagonist [EJNMMI radiopharmacy and chemistry · 2025Article
- Biological Evaluation of Molecular Spherical Nucleic Acids: Targeting Tumors via a Hybridization-Based Folate Decoration.ACS omega · 2025Article
- Harnessing Radionuclides: Unveiling the Promising Role of Radiopharmaceuticals in Cancer Theranostics and Palliative Care.Current radiopharmaceuticals · 2025Review
- Nuclear Imaging of Bispecific Antibodies on the Rise.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Review
- One-Step Synthesis of [ACS central science · 2024Article
- Trans-cyclooctene-a Swiss army knife for bioorthogonal chemistry: exploring the synthesis, reactivity, and applications in biomedical breakthroughs.EJNMMI radiopharmacy and chemistry · 2024Review
- Synthesis and evaluation of fluorine-18 labelled tetrazines as pre-targeting imaging agents for PET.EJNMMI radiopharmacy and chemistry · 2024Article
- Development of a 99mTc-labeled tetrazine for pretargeted SPECT imaging using an alendronic acid-based bone targeting model.PloS one · 2024Article
- Preclinical evaluation of Affibody molecule for PET imaging of human pancreatic islets derived from stem cells.EJNMMI research · 2023Article
- Click Chemistry and Radiochemistry: An Update.Bioconjugate chemistry · 2023Review
- Imaging of fibrogenesis in the liver by [EJNMMI radiopharmacy and chemistry · 2023Article
- Highlights on U.S. FDA-approved fluorinated drugs over the past five years (2018-2022).European journal of medicinal chemistry · 2023Review
- ImmunoPET Directed to the Brain: A New Tool for Preclinical and Clinical Neuroscience.Biomolecules · 2023Review
- Development of brain-penetrable antibody radioligands forFrontiers in nuclear medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibodies are attractive as radioligands due to their outstanding specificity and high affinity, but their inability to cross the blood-brain barrier (BBB) limits their use for CNS targets. To enhance brain distribution, amyloid-β (Aβ) antibodies were fused to a transferrin receptor (TfR) antibody fragment, enabling receptor mediated transport across the BBB. The aim of this study was to label these bispecific antibodies with fluorine-18 and use them for Aβ PET imaging. Bispecific antibody ligands RmAb158-scFv8D3 and Tribody A2, both targeting Aβ and TfR, were functionalized with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.